After the publication of this study [1] an error was detected in Fig. 2e. The same image was accidently used for beta-catenin staining of MCF7 2A-1 and T47D 2A-4. This error does not affect the findings or conclusions of the article. The corrected figure is shown below and we apologise for this mistake.
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.